New Enhanced OMIDRIAssure® Patient Access Programs

Learn more

Real-world evidence

Welcome A Cascade of Positive Outcomes

Patients treated with OMIDRIA had an 78.4% reduction in complications rates compared to Epinephrine (3.7% vs 0.8%)

Fewer intraoperative and postoperative complications with OMIDRIA, including capsular tears, lens decentration, retained lens fragments, macular puckering, and retinal detachment.1*

*Single-center, retrospective case review.1

Retrospective, 2-cohort study.2

Single-center, retrospective case review (N=641)1

A single-center, retrospective case review of patients undergoing cataract surgery who received OMIDRIA or epinephrine

All patients received a topical NSAID regimen for 3 days before surgery and topical tropicamide 1.0%, cyclopentolate 1.0%, and phenylephrine 2.5% on the day of surgery.1

Retrospective, 2-cohort study (N=2218)2

In a retrospective, 2-cohort study, the incidence of CME, breakthrough iritis, and pain were compared between patients who received OMIDRIA or topical loteprednol

All eyes in both groups received bromfenac ophthalmic solution 0.07% for 2 days prior to surgery and 10 weeks postoperatively.2

REFERENCES: 1. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. Clin Ophthalmol. 2018;12:21-28. 2. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg. 2020;46(6):867-872.